Use of multimodality imaging to diagnose cardiac sarcoidosis as well as identify recurrence following heart transplantation

Osborne, Michael T.; Kolli, Swathy; Padera, Robert F.; Naya, Masanao; Lewis, Eldrin F.; Dorbala, Sharmila; Carli, Marcelo F. Di; Blankstein, Ron

doi:10.1007/s12350-013-9677-3

Cited by 21 publications

(4 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The presence of both focal perfusion defect and FDG uptake predicts a poor outcome in patients with known or suspected CS. However, the heterogeneity of spatial abnormality was not taken into consideration in that study (4), although inflammation and scar lesions are heterogeneous in the heart (5). Accordingly, the precise evaluation of the disease heterogeneity should improve the diagnostic and prognostic values.…”

Section: Data Analysis For Cardiac Sarcoidosismentioning

confidence: 98%

Nuclear Medicine Image Interpretation Progress in the Assessment of Cardiac Sarcoidosis: July <b>2019</b> ASNC/JSNC Joint Session

Naya

Manabe

2020

Annals of Nuclear Cardiology

Self Cite

View full text Add to dashboard Cite

Sarcoidosis is a significant disease affecting the heart.18 F-fluorodeoxyglucose (FDG) positron emission tomography (PET) is a well-validated method for identifying significant focal inflammatory sarcoid lesions. The recent progress in image interpretation in nuclear medicine improves the diagnosis and the risk stratification in patients with cardiac sarcoidosis. Especially, metabolic activity, texture analysis, phase analysis, right ventricle assessment, and digital PET/CT are promising methods to assess cardiac sarcoidosis. This review focuses on the latest data analyses and image interpretation used in nuclear medicine to assess cardiac sarcoidosis.

show abstract

Section: Data Analysis For Cardiac Sarcoidosismentioning

confidence: 98%

Nuclear Medicine Image Interpretation Progress in the Assessment of Cardiac Sarcoidosis: July <b>2019</b> ASNC/JSNC Joint Session

Naya

Manabe

2020

Annals of Nuclear Cardiology

Self Cite

View full text Add to dashboard Cite

show abstract

“…74 There is some theoretical risk of sarcoidosis recurrence in the transplanted heart, but in published case reports this is typically in the setting of weaning off corticosteroids. 75,76 More contemporary single-centre case series of cardiac transplantation in CS have reported no recurrence of CS in the allograft. 72,77 After transplantation, the general approach is to maintain indefinite low-dose prednisone therapy in patients transplanted for CS.…”

Section: Catheter Ablationmentioning

confidence: 99%

Management of cardiac sarcoidosis

Sharma,

Kouranos,

Cooper

et al. 2024

European Heart Journal

View full text Add to dashboard Cite

Cardiac sarcoidosis (CS) is a form of inflammatory cardiomyopathy associated with significant clinical complications such as high-degree atrioventricular block, ventricular tachycardia, and heart failure as well as sudden cardiac death. It is therefore important to provide an expert consensus statement summarizing the role of different available diagnostic tools and emphasizing the importance of a multidisciplinary approach. By integrating clinical information and the results of diagnostic tests, an accurate, validated, and timely diagnosis can be made, while alternative diagnoses can be reasonably excluded. This clinical expert consensus statement reviews the evidence on the management of different CS manifestations and provides advice to practicing clinicians in the field on the role of immunosuppression and the treatment of cardiac complications based on limited published data and the experience of international CS experts. The monitoring and risk stratification of patients with CS is also covered, while controversies and future research needs are explored.

show abstract

“…CMR and nuclear imaging offer a significant contribution in diagnosing and characterising the underlying disease, notably in the assessment of cardiac sarcoidosis by PET imaging [111] and amyloidosis by CMR. This is a consequence of myocardial disease which may be classified as primary or secondary.…”

Section: Infiltrative Disease/restrictive Cardiomyopathymentioning

confidence: 99%